Maintenance: Wednesday, 22 November 2017, 07:00-08:00
Maintenance work on the ZORA servers is provided. There may be short interruptions in the service between 07:00 and 08:00. Thank you for your patience.
Widenmeyer, M; Griesemann, H; Stevanović, S; Feyerabend, S; Klein, R; Attig, S; Hennenlotter, J; Wernet, D; Kuprash, D V; Sazykin, A Y; Pascol, S; Stenzl, A; Gouttefangeas, C; Rammensee, H G (2012). Promiscuous survivin peptide induces robust CD4+ T-cell responses in the majority of vaccinated cancer patients. International Journal of Cancer, 131(1):140-149.
Widenmeyer, M; Shebzukhov, Y; Haen, S P; Schmidt, D; Clasen, S; Boss, A; Kuprash, D V; Nedospasov, S A; Stenzl, A; Aebert, H; Wernet, D; Stevanovic, S; Pereira, P L; Rammensee, H G; Gouttefangeas, C (2011). Analysis of tumor antigen-specific T cells and antibodies in cancer patients treated with radiofrequency ablation. International Journal of Cancer, 128(11):2653-2662.
Shebzukhov, Y V; Lavrik, I N; Karbach, J; Khlgatian, S V; Koroleva, B P; Belousov, P V; Kashkin, K N; Knuth, A; Jager, E; Chi, N W; Kuprash, D V; Nedospasov, S A (2008). Human tankyrases are aberrantly expressed in colon tumors and contain multiple epitopes that induce humoral and cellular immune responses in cancer patients. Cancer Immunology, Immunotherapy, 57(6):871-881.
Junt, T; Tumanov, A V; Harris, N; Heikenwalder, M; Zeller, N; Kuprash, D V; Aguzzi, A; Ludewig, B; Nedospasov, S A; Zinkernagel, R M (2006). Expression of lymphotoxin beta governs immunity at two distinct levels. European Journal of Immunology, 36(8):2061-2075.